---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021955"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:43:06.403881+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics loses Head of Development; internal replacement named

## Summary
- Rob Schott, M.D., SVP Head of Development, resigns effective August 19, 2022 to pursue new opportunity.
- Resignation not due to any disagreement with the Company on operations, financial statements, or policies.
- Nathalie Dubois-Stringfellow, Ph.D., currently SVP Product Development, will succeed as SVP Head of Development.

## SEC filing metadata
- accession: 0001628280-22-021955
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828022021955/0001628280-22-021955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828022021955/sgmo-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021955
- JSON: https://secwatch.observer/filing/0001628280-22-021955.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021955.txt

## Key facts
- Executive change
  Rob Schott resigned as Senior Vice President, Head of Development at SANGAMO THERAPEUTICS, INC.
  - Action: resigned
  - Role: Senior Vice President, Head of Development
  source text: On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President, Head of Development of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his resignation from this position and from his employment with the Company, with such resignation to be effective on August 19, 2022, in order to pursue a new opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828022021955/0001628280-22-021955-index.htm
- Executive change
  Nathalie Dubois-Stringfellow was appointed as Senior Vice President, Head of Development at SANGAMO THERAPEUTICS, INC.
  - Action: appointed
  - Role: Senior Vice President, Head of Development
  source text: Effective August 19, 2022, Nathalie Dubois-Stringfellow, Ph.D., currently serving as Senior Vice President, Product Development and Management, will assume the role of Senior Vice President, Head of Development of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828022021955/0001628280-22-021955-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.